Day: November 15, 2024

Consolidated Interim report 1 January – 30 September 2024

Written by Customer Service on November 15, 2024. Posted in Earnings Releases And Operating Results.

Consolidated Interim report 1 January – 30 September 2024 Company announcement no. 30 – November 15, 2024Key points from the Q1-Q3-2024 report (period 1 January – 30 September 2024) On 15 November 2024, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “the Company” or “the Group”) considered and approved the interim report for the Group for the period 1 January – 30 September 2024 (“Q1-Q3 2024 report”). The report has not been audited or reviewed. Products and patents On 23 October 2024, in company announcement no. 29, the Company announced that the Company’s subsidiary, Reponex Pharmaceuticals A/S (Reponex), had announced that the Japan Patent Office had issued a patent regarding patent application no. 7562413. The patent concerns Reponex’s...

Interim Report – January-September 2024

Written by Customer Service on November 15, 2024. Posted in Earnings Releases And Operating Results.

STOCKHOLM – 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report – January-September 2024. The full report is available on the Company’s website. “Research progress is an important element and one that generates value in our portfolio companies, so it’s particularly pleasing when a so newly added company, such as BOOST Pharma, delivers strong data at an early stage in the process. We now have an investment portfolio in which several of our portfolio companies have achieved a degree of maturity that offers considerable potential for realizing increases in value through exits over the coming years”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the third quarterThe portfolio company Umecrine Cognition conducted a capital raise, implemented as a...

PARROT: 2024 3rd quarter business

Written by Customer Service on November 15, 2024. Posted in Earnings Releases And Operating Results.

PRESS RELEASE November 15, 2024 at 8:00am CET 2024 3rd quarter business Consolidated revenues of €21,0 million (+39%) The Parrot group, European leader for professional microdrones, recorded revenues of €21.0 million for the third quarter of 2024, with a +39% growth. The professional microdrones business is up +70% and the Photogrammetry business is up +4%. At this level of activity, the Group’s current operations are close to break even. Over 9 months, consolidated revenues came to €51.6 million, up +11%.REVENUESin € million and % of revenues Q3 20233 months Q3 2024(1)3 months Change FY 202312 month Professional microdrones(2) 8,0 53% 13,6 65% +70% 33,2 51% Photogrammetry 7,1 47% 7,4 35% +4% 31,8 49%TOTAL PARROT GROUP(3) 15,1 100% 21,0 100% +39% 65,0 100%(1) The 3rd quarter 20024 financial statements,...

Bavarian Nordic Announces Interim Results for the First Nine Months of 2024

Written by Customer Service on November 15, 2024. Posted in Earnings Releases And Operating Results.

COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024.Revenue for the first nine months was DKK 3,622 million, and the operating profit (EBITDA) was DKK 692 million. Revenue from Travel Health increased by 18% to DKK 1,892 million compared to the first nine months of 2023 and revenue from Public Preparedness was DKK 1,549 million, which is in line with the Company’s expectations. Other revenue was DKK 181 million. The financial guidance for the full year, which was upgraded on September 26 as a result of additional mpox vaccine orders and improved performance in the Travel Health business, is maintained at a revenue between DKK 5,400 million and DKK 5,800 million and EBITDA between DKK...

BW Offshore: Third quarter results 2024

Written by Customer Service on November 15, 2024. Posted in Earnings Releases And Operating Results.

Third quarter results 2024 HIGHLIGHTSEBITDA USD 83 million Net profit USD 13 million Operating cashflow USD 86 million Equity ratio 29.6% and USD 707 million in available liquidity Q3 cash dividend USD 0.0625 per share equivalent to USD 11 million Barossa FPSO 90% completed, additional costs to close variation orders and maintain schedule Full year 2024 EBITDA expectation increased to USD 315 – 320 millionBW Offshore continues to progress the Barossa project according to schedule. As of end October 2024, the project was 90% completed. BW Opal is undergoing commissioning and preparations for sail-away from the yard in Singapore, where it will be towed to the field in Australia. Closing out variation orders and prioritising the schedule, combined with additional manhours at the yard, is expected to lead to net additional investments...

Vallourec Third Quarter 2024 Results

Written by Customer Service on November 15, 2024. Posted in Earnings Releases And Operating Results.

Meudon (France), November 15th, 2024 Vallourec, a world leader in premium tubular solutions, announces today its results for the third quarter 2024. The Board of Directors of Vallourec SA, meeting on November 14th 2024, approved the Group’s third quarter 2024 Consolidated Financial Statements. Third Quarter 2024 ResultsQ3 EBITDA of €168m, EBITDA margin remained strong at 19% Very strong total cash generation, with €130 million in Q3 Net debt now €240 million, marking eighth consecutive quarter of deleveraging Group full year EBITDA guidance of €800 – €850 million confirmed; Q4 EBITDA to increase sequentially Vallourec confirms total cash generation in Q3 and future periods will be subject to its 80 – 100% payout ratio Vallourec plans to announce dividend proposal for 2025 AGM with Full Year 2024 results communicationaHIGHLIGHTS Third...

Pressure Vessels Market to Surpass Valuation of USD 77.46 Billion by 2031 | SkyQuest Technology

Written by Customer Service on November 15, 2024. Posted in Mergers And Acquisitions.

Pressure Vessels Market size was valued at USD 48.24 billion in 2023 to USD 77.46 billion by 2031, growing at a CAGR of 6.1% in the forecast period (2024-2031). Westford, USA, Nov. 14, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global pressure vessels market size will reach a value of USD 77.46 Billion by 2031, with a CAGR of 6.1% during the forecast period (2024-2031). The substantial growth of the chemical and petrochemical sectors as well as the increasing use of supercritical power generation technology are responsible for this industry boom. Pressure containers have beneficial properties including corrosion and cross-contamination resistance. They are therefore employed in a number of chemical processes. As a result, it is anticipated that the chemical industry’s explosive growth and the advantages the product...

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Written by Customer Service on November 15, 2024. Posted in Public Companies.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticariaResubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target...

Richemont’s 2024 Interim Report now available online

Written by Customer Service on November 15, 2024. Posted in Public Companies.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR 15 NOVEMBER 2024 RICHEMONT’S 2024 INTERIM REPORT NOW AVAILABLE ONLINE Richemont announces the publication of its interim report and accounts for the six months ended 30 September 2024. The report is available for download from the Richemont website at: www.richemont.com/investors/results-reports-presentations/ The interim report reflects the information contained in the Richemont results announcement issued on 8 November 2024 as well as the unaudited condensed interim consolidated financial statements posted on the Group’s website the same day. In accordance with stock exchange regulations in Switzerland and South Africa, Richemont no longer prints its interim report. About Richemont At Richemont, we craft the future. Our unique portfolio includes prestigious Maisons distinguished by their craftsmanship...

Aegon trading update for third quarter 2024

Written by Customer Service on November 15, 2024. Posted in Public Companies.

The Hague, November 15, 2024 – Please click here to access all 3Q 2024 trading update related documents. EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously Capital ratios of the main units remain above their respective operating levels Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026 Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted...

Day: November 15, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals